Droperidol was a first-line, highly effective agent for the treatment of PONV for over 30 years. It has the most postmarketing surveillance data of any of the currently used antiemetic agents. Yet ...
Summary: A written request was submitted to FDA to provide a report of any and all reports of cardiovascular adverse events related to droperidol that were part of the decision to add a black-box ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback